Lifecore Biomedical (LFCR) Expected to Announce Earnings on Thursday

Lifecore Biomedical (NASDAQ:LFCR) is expected to be issuing its quarterly earnings data after the market closes on Thursday, April 3rd. Analysts expect the company to post earnings of ($0.14) per share and revenue of $33.23 million for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Lifecore Biomedical (NASDAQ:LFCR) last released its quarterly earnings data on Thursday, January 2nd. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.02. Lifecore Biomedical had a negative net margin of 12.52% and a negative return on equity of 315.23%. On average, analysts expect Lifecore Biomedical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Lifecore Biomedical Stock Down 0.1 %

LFCR opened at $7.03 on Wednesday. Lifecore Biomedical has a one year low of $3.68 and a one year high of $7.99. The company has a debt-to-equity ratio of 9.21, a quick ratio of 1.21 and a current ratio of 2.32. The stock has a market capitalization of $260.29 million, a P/E ratio of -12.55 and a beta of 0.96. The business’s 50-day simple moving average is $6.16 and its 200-day simple moving average is $6.23.

Analysts Set New Price Targets

Separately, Stephens reaffirmed an “equal weight” rating and set a $6.00 price target on shares of Lifecore Biomedical in a research report on Friday, January 3rd.

Insiders Place Their Bets

In other Lifecore Biomedical news, CEO Paul Josephs bought 17,000 shares of the firm’s stock in a transaction dated Wednesday, January 8th. The stock was acquired at an average price of $5.74 per share, for a total transaction of $97,580.00. Following the completion of the purchase, the chief executive officer now owns 559,717 shares of the company’s stock, valued at approximately $3,212,775.58. This represents a 3.13 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 32.20% of the stock is currently owned by insiders.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.